• Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee®, in Australia

    • October 3, 2019
    • Posted By : admin
    • 0 Comment
    •   17 views

    Biocon Ltd and Mylan N.V. today announced the launch of Semglee® (insulin glargine solution for injection 100 IU/mL in a 3mL pre-filled pen), the first insulin glargine biosimilar in Australia available on the Pharmaceutical Benefits Scheme (PBS).

    Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar levels of those with diabetes. It is indicated for the treatment of type 1 diabetes mellitus in adults, adolescents and children aged six years and above and type 2 diabetes mellitus in adults. Diabetes is recognised as the world’s fastest growing chronic condition and is the biggest challenge confronting Australia’s health system. Almost two million Australians have diabetes, with 280 Australian developing diabetes every day – one person every five minutes. The total annual cost impact of diabetes in Australia is estimated at $14.6 billion.1

    More affordable treatment options for healthcare providers and their patients, such as biosimilars, generate savings that help manage the growing costs of Australia’s health care system, particularly the PBS.

    The Government recognises the importance of driving biosimilar uptake to create a competitive and sustainable biosimilars market. In 2015, the Government committed to the Biosimilar Awareness Initiative and in 2018 increased its commitment by supporting the Generic and Biosimilar Medicines Association through a $5 million grant to undertake activities that further promote the appropriate prescribing, dispensing and use of biosimilar medicines.

  17 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!